Comparison · NCT00294047-d0e0323a
Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects Reporting Any AE/SAE Leading to Premature Discontinuation of the Study.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects Reporting Any AE/SAE Leading to Premature Discontinuation of the Study. Trial comparisons, record NCT00294047-d0e0323a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00294047-d0e0323a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00973 | 0.00674 | 0.014 | wilson | |
| Risk in group 2 | 0.00488 | 0.00291 | 0.00817 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00485 | 0.000406 | 0.00958 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2 | 1.05 | 3.78 | log | |
| Odds ratio, group 1 over group 2 | 2 | 1.05 | 3.82 | log | |
| Number needed to treat, for one more participant with the outcome on Cervarix Group than on Aluminium Hydroxide Group | 206 | 104 | 2,460 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cervarix Group | Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule. | 28 | 2,877 | OG000 |
| Group 2 | Aluminium Hydroxide Group | Subjects received 3 doses of Aluminium Hydroxide \[Al(OH)3\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule. | 14 | 2,870 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Reporting Any AE/SAE Leading to Premature Discontinuation of the Study.
- Description
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.~Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
- Time frame
- Up to Month 84
- Population
- The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.
Source ClinicalTrials.gov
Trial
- Title
- Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
- NCT number
- NCT00294047
- Phases
- PHASE3
- Conditions
- Infections, Papillomavirus, Papillomavirus Vaccines
- Interventions
- Cervarix, Placebo control
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2012-03-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00294047?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00294047-d0e0323a